– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing myeloablative conditioning as seen in younger patients across disease control, non-relapse mortality and overall survival –– Orca-T in older patients given a reduced intensity conditioning regim.
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy to that of standard allogeneic transplant in younger and older patients with hematologic malignancies, according to data from a phase 1b study.